Last reviewed · How we verify

Eplerenone vs Amlodipine

Brigham and Women's Hospital · FDA-approved active Small molecule

Eplerenone vs Amlodipine is a Aldosterone antagonist (eplerenone); Dihydropyridine calcium channel blocker (amlodipine) Small molecule drug developed by Brigham and Women's Hospital. It is currently FDA-approved for Hypertension (both agents), Heart failure with reduced ejection fraction (eplerenone), Post-myocardial infarction with left ventricular dysfunction (eplerenone).

This is a comparison of two marketed cardiovascular drugs: eplerenone, a selective aldosterone antagonist, and amlodipine, a calcium channel blocker, each working through different pathways to lower blood pressure.

This is a comparison of two marketed cardiovascular drugs: eplerenone, a selective aldosterone antagonist, and amlodipine, a calcium channel blocker, each working through different pathways to lower blood pressure. Used for Hypertension (both agents), Heart failure with reduced ejection fraction (eplerenone), Post-myocardial infarction with left ventricular dysfunction (eplerenone).

At a glance

Generic nameEplerenone vs Amlodipine
SponsorBrigham and Women's Hospital
Drug classAldosterone antagonist (eplerenone); Dihydropyridine calcium channel blocker (amlodipine)
TargetMineralocorticoid receptor (eplerenone); L-type voltage-gated calcium channel (amlodipine)
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Eplerenone blocks aldosterone receptors in the kidney and heart, reducing sodium retention and blood volume while providing cardiac protection in heart failure and post-MI settings. Amlodipine blocks L-type calcium channels in vascular smooth muscle, causing vasodilation and reducing peripheral vascular resistance to lower blood pressure. These agents represent different mechanistic approaches to hypertension and cardiovascular disease management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Eplerenone vs Amlodipine

What is Eplerenone vs Amlodipine?

Eplerenone vs Amlodipine is a Aldosterone antagonist (eplerenone); Dihydropyridine calcium channel blocker (amlodipine) drug developed by Brigham and Women's Hospital, indicated for Hypertension (both agents), Heart failure with reduced ejection fraction (eplerenone), Post-myocardial infarction with left ventricular dysfunction (eplerenone).

How does Eplerenone vs Amlodipine work?

This is a comparison of two marketed cardiovascular drugs: eplerenone, a selective aldosterone antagonist, and amlodipine, a calcium channel blocker, each working through different pathways to lower blood pressure.

What is Eplerenone vs Amlodipine used for?

Eplerenone vs Amlodipine is indicated for Hypertension (both agents), Heart failure with reduced ejection fraction (eplerenone), Post-myocardial infarction with left ventricular dysfunction (eplerenone), Angina pectoris (amlodipine).

Who makes Eplerenone vs Amlodipine?

Eplerenone vs Amlodipine is developed and marketed by Brigham and Women's Hospital (see full Brigham and Women's Hospital pipeline at /company/brigham-and-women-s-hospital).

What drug class is Eplerenone vs Amlodipine in?

Eplerenone vs Amlodipine belongs to the Aldosterone antagonist (eplerenone); Dihydropyridine calcium channel blocker (amlodipine) class. See all Aldosterone antagonist (eplerenone); Dihydropyridine calcium channel blocker (amlodipine) drugs at /class/aldosterone-antagonist-eplerenone-dihydropyridine-calcium-channel-blocker-amlodipine.

What development phase is Eplerenone vs Amlodipine in?

Eplerenone vs Amlodipine is FDA-approved (marketed).

What are the side effects of Eplerenone vs Amlodipine?

Common side effects of Eplerenone vs Amlodipine include Hyperkalemia, Gynecomastia, Peripheral edema, Headache, Flushing, Dizziness.

What does Eplerenone vs Amlodipine target?

Eplerenone vs Amlodipine targets Mineralocorticoid receptor (eplerenone); L-type voltage-gated calcium channel (amlodipine) and is a Aldosterone antagonist (eplerenone); Dihydropyridine calcium channel blocker (amlodipine).

Related